ML2006a4_product_DataBase

Bioactivity	ML2006a4 is an orally active inhibitor for SARS-CoV-2 main protease (Mpro) with IC50 in picomolare value. ML2006a4 is cell permeable and antiviral active, that inhibits replication in SARS-CoV-2 in cells Huh7.5.1-ACE2-TMPRSS2 (Huh7.5.1++) in picomolare level[1]
Invitro	ML2006a4 (0-10 μM) 在细胞 Huh7.5.1++ 和 A549-ACE2 (A549+) 中具有抗病毒活性，EC50 分别为 100 和 120 nM[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> ML2006a4 相关抗体:
In Vivo	ML2006a4 (20 mg/kg，静脉注射) 的药代动力学曲线显示，ML2006a4 的血浆清除率 Cpl 为 39 mL/min/kg，稳态分布容积 Vss 0.66 L/kg，口服生物利用度为 27% (40 mg/kg，口服)[1]。ML2006a4 (40 mg/kg，口服，每天 2 次，共 4 天) 可改善 SARS-CoV-2 感染，对 BALB/c 小鼠表现出病毒抑制和肺保护作用，且无明显毒性[1] 。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model:
CAS	2943213-62-3
Formula	C30H44F3N5O6
Molar Mass	627.70
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Westberg M, et al., An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations. Sci Transl Med. 2024 Mar 13;16(738):eadi0979.

PeptideDB